secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008307
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology doses first subject in Phase 1 trial of ADC PYX-201 for solid tumors
--------------------------------------------------------------------------------

- First subject dosed in open-label, dose-escalation Phase 1 trial PYX-201-101; preliminary data expected early 2024.
- PYX-201 targets EDB fibronectin, overexpressed in many solid tumors; minimal expression in normal adult tissues.
- Trial enrolling patients with NSCLC, HR+ breast, ovarian, thyroid, pancreatic, sarcoma, hepatocellular, kidney cancers.
- PYX-201 uses FACT platform licensed from Pfizer (2021) for site-specific conjugation and improved safety profile.
- Dosing milestone marks transition of Pyxis Oncology to a clinical-stage company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023008307/0000950170-23-008307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023008307/pyxs-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer